Delcath stock.

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...Nov 22, 2023 · When we look at Delcath Systems Inc’s average trading volume, we note the 10-day average is 0.54 million shares, with the 3-month average coming to 413.15K. Analysts gave the Delcath Systems Inc (DCTH) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. Find real-time DCTH - Delcath Systems Inc stock quotes, company profile, news and forecasts from CNN Business. finance.yahoo.com - September 5 at 5:40 PM. Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™. finance.yahoo.com - September 1 at 3:21 PM. Delcath Systems (DCTH) Price Target Increased by 10.98% to 18.56.5.9000. 6.1920. 6.1920. 53,900. *Close price adjusted for splits. **Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data... Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued.

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that ...Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued.Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued.

About Us. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products are HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP). With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

eRecent News [2022-12-16] Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4) [2022-12-13] Delcath Systems Closes Private Placement of $6.2 Million [2022-12-08] Delcath Systems Announces Private Placement of $6.2 Million [2022-12-05] Results of a Single Center Study on Delcath’s …At one point, Delcath's stock was delisted from NASDAQ and share price was trading at 2 cents on OTC exchange before numerous reverse splits. Investors have written off Delcath and thought it was ...Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued.Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. We are a specialty pharmaceutical and medical device company developing our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

On average, Wall Street analysts predict that Delcath Systems's share price could reach $18.00 by Sep 7, 2024. The average Delcath Systems stock price ...

Delcath is in the process of completing its customary quarter-end close and review procedures, including certain valuation work associated with the issuance of warrants and preferred stock in ...

In the last 3 months, 5 analysts have offered 12-month price targets for Delcath Systems. The company has an average price target of $17.2 with a high of $20.00 and a low of $13.00. Below is a ...Nov 30, 2023 · Dividends. A high-level overview of Delcath Systems, Inc. (DCTH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. In other news, COO John Purpura bought 14,505 shares of Delcath Systems stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.44 per share, for a total transaction of $49,897.20. Following the purchase, the chief operating officer now owns 41,526 shares of the company’s stock, valued at $142,849.44.What this means: Delcath Systems Inc (DCTH) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.As described in Item 5.07 of this Current Report on Form 8-K, on July 19, 2016, at its 2016 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of Delcath Systems, Inc. (the “Company”) approved the Amended and Restated 2009 Stock Incentive Plan (the “Plan”).No changes to the price of Delcath Systems stock on the last trading day (Friday, 7th Feb 2020). During the last trading day the stock fluctuated 0% from a day low at $10.25 to a day high of $10.25.The price has fallen in 5 of the last 10 days and is down by -39.71% for this period.Stock analysis for Delcath Systems Inc (DCTH:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Crazy to sell under $8.5-9 "Delcath Systems price target raised to $18 from $14 at Canaccord Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on ...DCTH | 1 hour ago. NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee ...May 12, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business ... See the latest Delcath Systems Inc stock price (DCTH:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Aug 11, 2023 · I believe Delcath Systems' ( NASDAQ: DCTH) HEPZATO KIT should be approved by the FDA on its PDUFA date, in spite of the recent sell-off resulting from concerns about DCTH’s API supplier. 1) DCTH ...

Delcath Systems to raise $5M in stock and warrants offering SA News Mon, Jul. 18, 2022 Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07MIn the last 3 months, 5 analysts have offered 12-month price targets for Delcath Systems. The company has an average price target of $17.2 with a high of $20.00 and a low of $13.00.

prec14a 1 a42519.htm delcath systems, inc. united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. __) r.Dec 1, 2023 · Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.10. The business earned $0.43 million during the quarter, compared to the consensus estimate of $0.68 million. According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 542.86% from the latest price.0001564590-15-006231.txt : 20150805 0001564590-15-006231.hdr.sgml : 20150805 20150805161855 ACCESSION NUMBER: 0001564590-15-006231 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTAccording to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Find the latest Delcath Systems, Inc. (DCTH) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 11/24/2023 the closing price of the Delcath Systems Inc …Delcath Systems, Inc. (NASDAQ:DCTH – Free Report) – Stock analysts at HC Wainwright lowered their FY2023 earnings per share estimates for shares of Delcath Systems in a report issued on Tuesday, November 14th.HC Wainwright analyst S. Ramakanth now expects that the company will earn ($3.17) per share for the year, down …09 Aug, 2023, 17:33 ET. NEW YORK, Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of ...

Find the latest Delcath Systems (DCTH) discussion and analysis from iHub's community of investors.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in New York, NY. DCTH - Delcath Systems Inc - Stock screener for investors and traders, financial visualizations.

DCTH Earnings Date and Information. Delcath Systems last posted its quarterly earnings data on November 13th, 2023. The reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.10. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.68 million.The 5 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 18.00, with a high estimate of 22.00 and a low estimate of ...Delcath Systems (DCTH) Company Description: Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers.Delcath Systems Probability Of Bankruptcy is currently at 95.49%. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress.52 Week High. $7.99. 52 Week Low. $2.25. Data as of November 24, 2023 1:00 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. undefined. See a complete list …Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug ...Delcath Systems story: What to Know About Buying Penny Stocks on June 7th StreetInsidercom and other headlines for Delcath SystemsDelcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in New York, NY. DCTH - Delcath Systems Inc - Stock screener for investors and traders, financial visualizations.PR Newswire (US) NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the ...Mar 27, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that ... Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of an article ...Dec 1, 2023 · According to the issued ratings of 4 analysts in the last year, the consensus rating for Delcath Systems stock is Buy based on the current 4 buy ratings for DCTH. The average twelve-month price prediction for Delcath Systems is $18.00 with a high price target of $21.00 and a low price target of $13.00. Learn more on DCTH's analyst rating history.

A Look At Delcath Systems' Liabilities . According to the last reported balance sheet, Delcath Systems had liabilities of US$11.1m due within 12 months, and liabilities of US$6.40m due beyond 12 months. Offsetting this, it had US$14.5m in cash and US$127.0k in receivables that were due within 12 months.Exhibit 10.1 . DELCATH SYSTEMS, INC. 2009 STOCK INCENTIVE PLAN (As amended and restated effective as of July 19, 2016) SECTION 1 Purpose . The purpose of this Delcath Systems, Inc. 2009 Stock Incentive Plan is to promote the interests of Delcath Systems, Inc. (the “Company”) and its Subsidiaries through grants of awards to …When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Instagram:https://instagram. ge dividendsunderstanding stock chartsscale ai ipobest currency trading sites DCTH: Delcath Systems Inc Stock Price Quote - NASDAQ CM - Bloomberg Subscribe S&P 500 4,567.80 +0.38% Nasdaq 14,226.22 –0.23% Crude Oil 75.62 … va lenders floridaairline reservation software DCTH | November 13, 2023. NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended … 1979 susan b anthony blob mint mark value This proxy statement is furnished to holders of common stock, $.01 per share, of Delcath Systems, Inc. (“Delcath” or the “Company”). The proxies are being solicited by the Board of Directors of Delcath for use at the 2009 Annual Meeting of Stockholders of Delcath to be held at 11:00 a.m. (Eastern Time) on Tuesday, June 9, 2009, at the Offices of Hughes …Nov 23, 2023 · In other news, COO John Purpura bought 14,505 shares of Delcath Systems stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.44 per share, for a total transaction of $49,897.20. Following the purchase, the chief operating officer now owns 41,526 shares of the company’s stock, valued at $142,849.44.